// App-Quantinova.ai

2573 : Early Response Dynamics Including Minimal Residual Disease (MRD) and Adherence to Risk/MRD-Oriented Therapy Are Major Outcome Determinants in Adult Ph-Negative Acute Lymphoblastic Leukemia (ALL).

Researchers

Presenter

  • Orietta Spinelli

Principal Investigators

  • Elena Oldani

  • Fabio Ciceri

  • Agostino Cortelezzi

  • Giacomo Gianfaldoni

  • Daniele Mattei

  • Ernesta Audisio

  • Tamara Intermesoli

  • Alessandro Rambaldi

  • Manuela Tosi

  • Barbara Peruta

  • Erika Borlenghi

  • Enrico Maria Pogliani

  • Eros Di Bona

  • Vincenzo Cassibba

  • Anna Maria Scattolin

  • Claudio Romani

Medical Centers

  • Hematology, Az. Osp. S. Croce e Carle, Cuneo, Italy

  • Hematology, Ospedale S. Bortolo, Vicenza, Italy

  • Hematology, Ospedale Civile, Bolzano, Italy

  • Division of Hematology, Ospedali Riuniti, Bergamo, Italy

  • UO oNcoematologia, IRCCS Ca Granda Ospedale Maggiore Policlinico and Universit degli Studi, Milano, Italy

  • Oncologia, Spedali Civili, Brescia, Italy

  • HSCT Adult Unit, Ospedale San Gerardo, Monza, Italy

  • Hematology, Ospedale Oncologico di Riferimento Regionale, Cagliari, Italy

  • Hematology , Ospedale San Giovanni Battista/Universita , Torino, Italy

  • Hematology, Universita di Firenze, AOU Careggi, Firenze, Italy

  • Hematology, Ospedale del-Angelo, Mestre-Venezia, Italy

  • Neuroradiology, San Raffaele Hospital, Milan, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • White Blood Cell

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved